Amgen Inc. $AMGN Position Raised by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 62.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,555 shares of the medical research company’s stock after acquiring an additional 2,904 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Amgen were worth $2,132,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Brighton Jones LLC grew its holdings in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC boosted its position in Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after acquiring an additional 114 shares during the period. Janney Capital Management LLC grew its stake in shares of Amgen by 27.6% in the second quarter. Janney Capital Management LLC now owns 1,037 shares of the medical research company’s stock worth $290,000 after purchasing an additional 224 shares in the last quarter. Union Bancaire Privee UBP SA increased its holdings in shares of Amgen by 94.4% during the second quarter. Union Bancaire Privee UBP SA now owns 4,432 shares of the medical research company’s stock valued at $1,237,000 after purchasing an additional 2,152 shares during the period. Finally, Alley Investment Management Company LLC increased its holdings in shares of Amgen by 1.1% during the second quarter. Alley Investment Management Company LLC now owns 25,052 shares of the medical research company’s stock valued at $6,995,000 after purchasing an additional 280 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the sale, the executive vice president directly owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 10,908 shares of company stock worth $3,674,966 in the last quarter. 0.69% of the stock is owned by company insiders.

Amgen Stock Down 2.6%

NASDAQ AMGN opened at $342.22 on Thursday. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $353.25. The company has a market capitalization of $184.28 billion, a P/E ratio of 26.45, a PEG ratio of 3.11 and a beta of 0.45. The company’s 50 day simple moving average is $332.38 and its 200 day simple moving average is $308.67. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.01 by $0.63. The firm had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is currently 73.57%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Argus upped their price objective on shares of Amgen from $310.00 to $360.00 and gave the stock a “buy” rating in a report on Tuesday, December 30th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Piper Sandler increased their price objective on shares of Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Deutsche Bank Aktiengesellschaft boosted their target price on Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a report on Tuesday, November 11th. Finally, Truist Financial upped their target price on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $339.71.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.